Prothena Corporation PLC (PRTA) to Release Earnings on Tuesday
Prothena Corporation PLC (NASDAQ:PRTA) will release its earnings data after the market closes on Tuesday, November 7th. Analysts expect the company to announce earnings of ($1.40) per share for the quarter.
Prothena Corporation PLC (NASDAQ:PRTA) last announced its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.43. The company had revenue of $26.81 million during the quarter, compared to the consensus estimate of $16.08 million. Prothena Corporation PLC had a negative return on equity of 33.20% and a negative net margin of 527.56%. The company’s revenue was up 7951.1% on a year-over-year basis. During the same period last year, the firm earned ($1.18) earnings per share. On average, analysts expect Prothena Corporation PLC to post $-4.51 EPS for the current fiscal year and $-5.17 EPS for the next fiscal year.
Shares of Prothena Corporation PLC (PRTA) traded up 0.26% during mid-day trading on Wednesday, hitting $58.20. The stock had a trading volume of 19,111 shares. The stock’s market cap is $2.23 billion. Prothena Corporation PLC has a 52 week low of $40.58 and a 52 week high of $70.00. The stock has a 50-day moving average price of $61.77 and a 200 day moving average price of $58.09.
A number of research analysts have weighed in on PRTA shares. Deutsche Bank AG reissued a “buy” rating on shares of Prothena Corporation PLC in a research report on Sunday, October 1st. Royal Bank Of Canada reissued a “buy” rating on shares of Prothena Corporation PLC in a research report on Friday, September 29th. Evercore ISI started coverage on shares of Prothena Corporation PLC in a research report on Wednesday, August 16th. They set an “outperform” rating and a $83.00 target price for the company. ValuEngine lowered shares of Prothena Corporation PLC from a “hold” rating to a “sell” rating in a research report on Friday, October 6th. Finally, Oppenheimer Holdings, Inc. reissued an “outperform” rating and set a $70.00 target price on shares of Prothena Corporation PLC in a research report on Thursday, July 6th. One research analyst has rated the stock with a sell rating and fourteen have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $78.58.
In other news, Director Christopher S. Henney sold 900 shares of the business’s stock in a transaction dated Thursday, September 28th. The shares were sold at an average price of $70.00, for a total transaction of $63,000.00. Following the transaction, the director now owns 900 shares in the company, valued at approximately $63,000. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Tara Nickerson sold 17,500 shares of the business’s stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $63.60, for a total transaction of $1,113,000.00. Following the transaction, the insider now owns 19,500 shares in the company, valued at approximately $1,240,200. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 29,424 shares of company stock worth $1,922,787. Insiders own 3.10% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/11/01/prothena-corporation-plc-prta-to-release-earnings-on-tuesday.html.
Prothena Corporation PLC Company Profile
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.